Guardant Health Inc’s recently made public that its Officer Eltoukhy Helmy acquired Company’s shares for reported $9.4 million on Dec 15 ’25. In the deal valued at $103.82 per share,90,565 shares were bought.
Then, Talasaz AmirAli sold 100,000 shares, generating $10,505,474 in total proceeds. Upon selling the shares at $105.05, the Co-Chief Executive Officer now owns 168,223 shares.
Before that, Kalia Kumud sold 2,000 shares. Guardant Health Inc shares valued at $209,204 were divested by the Chief Information Officer at a price of $104.60 per share. As a result of the transaction, Kalia Kumud now holds 22,365 shares, worth roughly $2.3 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in late September from “a Peer perform” to “an Outperform”. Mizuho started covering the stock on April 10, 2025. It rated GH as “an Outperform”.
Price Performance Review of GH
On Monday, Guardant Health Inc [NASDAQ:GH] saw its stock jump 0.59% to $102.67. Over the last five days, the stock has lost -1.44%. Guardant Health Inc shares have risen nearly 187.91% since the year began. Nevertheless, the stocks have risen 236.07% over the past one year. While a 52-week high of $112.43 was reached on 11/25/25, a 52-week low of $29.91 was recorded on 01/02/25.
Levels Of Support And Resistance For GH Stock
The 24-hour chart illustrates a support level at 101.58, which if violated will result in even more drops to 100.48. On the upside, there is a resistance level at 104.39. A further resistance level may holdings at 106.10.
How much short interest is there in Guardant Health Inc?
A steep rise in short interest was recorded in Guardant Health Inc stocks on 2025-11-28, growing by 0.83 million shares to a total of 9.25 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 8.42 million shares. There was a rise of 8.98%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 23, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
